HD-OPM Archive
Topics › Heart rhythm & heart failure

Stem-cell heart patch (BioVAT) raised ejection fraction at 3 months in phase 1-2 trial

Louis Nervegna · Jun 20, 2026 · ♥ 6 reactions · 1 comments · original Facebook post
Heart rhythm & heart failure
AI summary & key facts

Louis shares a NEJM interim report of a phase 1-2 trial in which stem-cell-derived engineered tissue was placed on the surface of failing human hearts. At 3 months it was associated with thicker target heart wall, higher ejection fraction and better quality-of-life scores, though every patient had at least one adverse event and longer follow-up is needed.

Links to articles on the study:

medpagetoday.comLink to medpagetoday.commedpagetoday.com healthmanagement.orgBiologic Ventricular Assist Tissue in Heart FailureA new article reports interim findings from the BioVAT-HF phase 1–2 clinical trial, which investigated a novel regenerative treatment for advanced heart…healthmanagement.org

Link to full study:

Paper · N Engl J Med · 2026Stem-Cell-Derived Biologic Ventricular Assist Tissue in Heart Failure.Conclusion: In this interim analysis, cardiac remuscularization with BioVAT was associated with an increase in the target heart-wall thickness, left ventricular ejection fraction, and KCCQ-OSS at 3 months; all the patients had at least one adverse event. Longer-term follow-up and further clinical investigation are warranted. (Funded by the German Center for Cardiovascular Research and Repairon; BioVAT-HF ClinicalTriapubmed.ncbi.nlm.nih.gov

#stemcellsHD #heartfailureHD

Research cited

Learn about the science behind a phase 1–2 study of stem-cell–derived ventricular assist tissue transplanted onto the epicardial surface of failing human hearts.

← newer: Daily peanut butter improved muscle power in older adults anolder: VITACOG: B vitamins cut brain atrophy 30% in mild cognitive →